Inverness' Rough Transition

At the rate Inverness Medical Innovations (AMEX: IMA ) has been buying up health-care companies, it wouldn't take too long for the company to become the next Johnson & Johnson (NYSE: JNJ ) .

Investors aren't so sure that the extrinsic growth is working the way Inverness planned it to. The stock was down 16% Wednesday to cap off a drop of more than 30% since the beginning of the year.

The company turned $27.6 million in adjusted non-GAAP net income in the fourth quarter into a GAAP loss of $12.5 million because of amortizations and one-time charges, including those associated with the acquisitions of Diamics, Cholestech, HemoSense, and BBI Holdings. That's a whole lot of charges -- and a lot companies to be integrating at one time.

That's not even all of the recent additions. Since the close of the quarter, Inverness has also agreed to purchase Matria Health Care (Nasdaq: MATR ) . The $900 million deal was done in both cash and stock, so Matria's investors are also feeling the hurt from Inverness' recent stock price drop.

My guess is that investors are having trouble evaluating the company, with so many new additions and its joint venture with Procter & Gamble (NYSE: PG ) causing year-over-year comparisons to be difficult at best. Rather than holding onto a company that they don't fully understand, they're selling.

That's a pretty smart move from my perspective. Imagine all the money investors could have saved if they'd sold when they realized they didn't understand Enron's business.

That's not to say that I think Inverness is necessarily going down in flames. There are plenty of companies that have turned around after having extrinsic growing pains -- Invitrogen (Nasdaq: IVGN ) being a prime example. Now might be the perfect buying opportunity, but it's not clear -- to me at least -- how long the transition to becoming a conglomerate will take.

Takeover this Foolishness:

Best Odds in the Universe!
If you're interested in a 98.79% chance at beating the market... and a 70.84% chance at DOUBLING the market's return – Motley Fool Supernova could be just what you're looking for. And get this: We arrived at these odds from 10,000 random back-tested portfolios composed of Motley Fool Co-founder David Gardner's personal stock picks.

It's why David recently handpicked a small team of world-class portfolio managers. You see, he thinks these odds can get even better! And he'd like to prove it to you...

Simply enter your email address. And the answer to the question everybody is asking will be delivered to your inbox!

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.